Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;19(9):969-970.
doi: 10.1038/s41423-020-00633-0. Epub 2021 Jan 8.

CD226: a potent driver of antitumor immunity that needs to be maintained

Jiacheng Bi  1
Affiliations
Comment

CD226: a potent driver of antitumor immunity that needs to be maintained

Jiacheng Bi. Cell Mol Immunol. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Figures

Fig. 1
Fig. 1
The downregulation of CD226 on tumor-infiltrating CD8+ T cells impairs antitumor immunity. CD226 expression on CD8+ T cells is downregulated in the tumor microenvironment via both an Eomes-dependent transcriptional mechanism and a CD155-mediated posttranslational mechanism, leading to the dysfunctional status of CD8+ T cells and poor responses to checkpoint blockade immunotherapy. The absence of Eomes or a Y319F mutation in CD226 maintains the expression of CD226 on tumor-infiltrating CD8+ T cells, which results in increased antitumor responses and might facilitate checkpoint blockade immunotherapy
See this image and copyright information in PMC

Comment on

  • CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
    Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T. Braun M, et al. Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010. Immunity. 2020. PMID: 33053330
  • Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
    Weulersse M, Asrir A, Pichler AC, Lemaitre L, Braun M, Carrié N, Joubert MV, Le Moine M, Do Souto L, Gaud G, Das I, Brauns E, Scarlata CM, Morandi E, Sundarrajan A, Cuisinier M, Buisson L, Maheo S, Kassem S, Agesta A, Pérès M, Verhoeyen E, Martinez A, Mazieres J, Dupré L, Gossye T, Pancaldi V, Guillerey C, Ayyoub M, Dejean AS, Saoudi A, Goriely S, Avet-Loiseau H, Bald T, Smyth MJ, Martinet L. Weulersse M, et al. Immunity. 2020 Oct 13;53(4):824-839.e10. doi: 10.1016/j.immuni.2020.09.006. Immunity. 2020. PMID: 33053331

References

    1. Weulersse M, et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity. 2020;53:824–839. e810. doi: 10.1016/j.immuni.2020.09.006. - DOI - PubMed
    1. Braun M, et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity. 2020;53:805–823. e815. doi: 10.1016/j.immuni.2020.09.010. - DOI - PubMed
    1. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 2015;15:243–254. doi: 10.1038/nri3799. - DOI - PubMed
    1. Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–937. doi: 10.1016/j.ccell.2014.10.018. - DOI - PubMed
    1. Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 2018;19:723–732. doi: 10.1038/s41590-018-0132-0. - DOI - PubMed

Publication types

Substances

LinkOut - more resources